Literature DB >> 2126684

Striatal function in normal aging: implications for Parkinson's disease.

G V Sawle1, J G Colebatch, A Shah, D J Brooks, C D Marsden, R S Frackowiak.   

Abstract

Central to several current theories of the etiology of Parkinson's disease is the premise that the nigrostriatal dopaminergic system degenerates with normal aging. Much of the evidence for this assertion has come from postmortem neurochemical studies. We have used L-6-[18F] fluoro-Dopa and positron emission tomography in 26 healthy volunteers (age range, 27-76 years) to examine striatal and frontal cortical tracer uptake. Data have been analyzed by using a graphical approach to calculate an influx constant (Ki) for L-6-[18F]fluoro-Dopa uptake into the caudate, putamen, and medial frontal cortex of each subject. In the population studied, there was no decline in Ki with age for any of these structures. A series of physiological measurements made on the older subjects also showed few significant changes with age. The positron emission tomographic findings demonstrate preservation of nigrostriatal dopaminergic function in normal aging. The pathological process causing Parkinson's disease may operate closer to the time of presentation than has been suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126684     DOI: 10.1002/ana.410280611

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

Review 1.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

2.  Molecular imaging of cell transplantation in Parkinson's disease.

Authors:  Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04       Impact factor: 9.236

3.  Positron emission tomography studies of neurotransmitter systems.

Authors:  G V Sawle; D J Brooks
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

4.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

5.  The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

Authors:  C J Bench; A A Lammertsma; P M Grasby; R J Dolan; S J Warrington; M Boyce; K P Gunn; L Y Brannick; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Correlations of striatal dopamine synthesis with default network deactivations during working memory in younger adults.

Authors:  Meredith N Braskie; Susan M Landau; Claire E Wilcox; Stephanie D Taylor; James P O'Neil; Suzanne L Baker; Cindee M Madison; William J Jagust
Journal:  Hum Brain Mapp       Date:  2010-06-24       Impact factor: 5.038

7.  [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

Authors:  H M Ruottinen; J O Rinne; M Haaparanta; O Solin; J Bergman; V J Oikonen; I Järvelä; P Santavuori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

8.  Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

Authors:  C J Bench; A A Lammertsma; R J Dolan; P M Grasby; S J Warrington; K Gunn; M Cuddigan; D J Turton; S Osman; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

10.  Clinical and [18F] dopa PET findings in early Parkinson's disease.

Authors:  P K Morrish; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.